Table 2.
Summary of Treatment-Related Parameters.
| Treatment | PFS and OS | Adverse Events (%) | Drug Cost a ($/cycle) | Reference |
|---|---|---|---|---|
| First-line setting | ||||
| Clb | Median PFS, 18.0 months | Anemia, 27 Neutropenia, 12 Thrombocytopenia, 20 Infection, 4 |
Cycle 1: 249 Cycles 2–6: 166 |
Eichhorst [18] |
| F | ≥65-years; Median PFS, 19.0 months | Anemia,15 Neutropenia, 12 Thrombocytopenia, 15 Infection, 80 |
Cycle 1-6: 1089 | Eichhorst [18] |
| FR | Median PFS, 42.0 months | Anemia, 40 Neutropenia, 76 Thrombocytopenia, 20 Infection, 20 |
Cycle 1: 4454 Cycles 2–6: 5575 |
Woyach [19] |
| FCR | <65-years, 3-year PFS, 64% | Anemia, 6 | Cycle 1: 4098 | Hallek [5] |
| ≥65-years, 3-year PFS, 68% | Neutropenia, 30 | Cycles 2–6: 5220 | ||
| IGHV mutated, 3-year PFS, 80% | Thrombocytopenia, 9 | |||
| IGHV unmutated, 3-year PFS, 55% | Infection, 24 | |||
| GClb | Median PFS, 26.7 months | Anemia, 4 Neutropenia, 33 Thrombocytopenia, 10 Infection, 12 |
Cycle 1: 16,493 Cycles 2–6: 5537 |
Goede [4] |
| Clb+R | Median PFS, 16.3 months | Anemia, 4 Neutropenia, 28 Thrombocytopenia, 3 Infection, 14 |
Cycle 1: 3,488 Cycles 2–6: 3365 |
Goede [4] |
| BR | ≥65-years, Median PFS, 34.0 months | Anemia, 31 Neutropenia, 31 Thrombocytopenia, 35 Infection, 12 |
Cycle 1: 5,491 Cycles 2–6: 6612 |
Fischer [20] |
| Ibrutinib | 6-month PFS, 90% | Anemia, 6 | 7615/cycle | Burger [13] |
| Del(17p), 24-month PFS, 91% | Neutropenia, 10 Thrombocytopenia, 2 Infection, 6 Arterial fibrillation, 6 |
|||
| Relapse setting | ||||
| F | Median PFS, 14.8 months | Anemia, 80 | Cycles 1–6: 1089 | Niederle [21] |
| Median OS, 41.0 months | Neutropenia, 17 Thrombocytopenia, 60 Infection, 15 |
|||
| FCR | Median PFS, 28.0 months | Anemia, 24 | Cycle 1: 4098 | Wierda [22] |
| Median OS, 42.0 months | Neutropenia, 81 Thrombocytopenia, 34 Infection, 16 |
Cycles 2–6: 5220 | ||
| B | Median PFS, 20.1 months | Anemia, 4 | Cycles 1–6: 2363 | Niederle [21] |
| Median OS, 43.8 months | Neutropenia, 20 Thrombocytopenia, 7 Infection, 13 |
|||
| BR | 24-months PFS, 41% | Anemia, 14 | Cycle 1: 5491 | Seymour [23] |
| Median OS, 33.9 months | Neutropenia, 39 Thrombocytopenia, 10 Infection, 22 |
Cycles 2–6: 6612 | Fischer [24] | |
| Ibrutinib | 30-month PFS, 69% | Anemia, 0 | 7615/cycle | Byrd [25] |
| Del(17p), 30-month PFS, 48% | Neutropenia, 18 | |||
| 30 months OS, 79% | Thrombocytopenia, 10 | |||
| Del(17p), 30 months OS, 65% | Infection, 51 Arterial fibrillation, 6 |
|||
| Idelalisib+R | 24-week PFS, 93% | Anemia, 5 | Cycle 1: 10,838 | Furman [26] |
| 1-year OS, 92% | Neutropenia, 34 Thrombocytopenia, 10 Infection, 0 |
Cycle 2: 11,959 Cycles 3–6: 7473 Cycles 7-progression: 2987 |
||
| Venetoclax | 12-month PFS, 86% | Anemia, 11 | Cycle 1: 1761 | Seymour [23] |
| Del(17p), 12-month PFS, 82% | Neutropenia, 58 | Cycles 2– | ||
| 24-month OS, 92% | Thrombocytopenia, 6 | progression: | ||
| Del(17p), 12-month OS, 87% | Infection, 18 | 7615 | Stilgenbauer [27] | |
B, bendamustine; BR, bendamustine and rituximab; Clb, chlorambucil; Clb+R, chlorambucil and rituximab; del(17p), deletion at chromosome 17p targeting the TP53 gene; F, fludarabine; FCR, fludarabine, cyclophosphamide and rituximab; FR, fludarabine and rituximab; GClb, obinutuzumab and chlorambucil; IGHV, immunoglobulin heavy-chain variable; OS, overall survival; PFS, progression-free survival; R, rituximab. a All Costs are shown in 2019 Canadian dollars.